Literature DB >> 31258360

Increased EGFR mRNA Expression Levels in Non-Small Cell Lung Cancer.

Sener Tasdemir1, Serpil Taheri2, Hilal Akalin3, Olgun Kontas4, Omer Onal5, Yusuf Ozkul3.   

Abstract

OBJECTIVE: In this study, we investigated the frequency of Epidermal growth factor receptor (EGFR) gene mutations, the level of EGFR mRNA and protein expressions in Turkish population for indicating substantial differences in the frequency of EGFR mutations, EGFR amplification and EGFR protein expression between populations and the effect of these parameters in response to EGFR tyrosine kinase inhibitors.
MATERIALS AND METHODS: The study included 34 patients with non-small cell lung cancers. The RNA and DNA were extracted from the normal and tumor side of the lung tissue removed by surgery. To investigate the most common mutations in the EGFR gene, exon 19 was sequenced and mutation specific PCR was performed for detecting the L858R mutation in exon 21. EGFR mRNA expression was measured by relative quantitative reverse transcription PCR. The EGFR protein levels were detected with immunohistochemistry methods from the sections of the patients' paraffin blocks.
RESULTS: No EGFR mutation in exon 19 or L858R mutation in exon 21 were detected in the patients. Overexpression of EGFR gene mRNA was identified in 16 of 34 (%47) patients and overexpression of EGFR protein was detected in 15 of 34 (%44) patients. Statistical analysis was not significant for the correlation between sex, age, smoking, histopathology, pathological stage and overexpression of EGFR mRNA and protein.
CONCLUSION: It was found that in Turkish population, EGFR mutation in exon 19 and L858R mutation were very rare, EGFR protein expression was similar and EGFR mRNA expression significantly increased compared to the literature. Markedly increased EGFR mRNA expression ratios in the absence of activating mutations showed that identifying the EGFR mRNA expression level for prediction of response to EGFR tyrosine kinase inhibitors might be significant in the Turkish population.

Entities:  

Keywords:  EGFR; NSCLC; Turkey; mRNA; mutation; protein

Year:  2017        PMID: 31258360      PMCID: PMC6592454          DOI: 10.5152/eurasianjmed.2016.0237

Source DB:  PubMed          Journal:  Eurasian J Med        ISSN: 1308-8734


  46 in total

1.  Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival.

Authors:  J Brabender; K D Danenberg; R Metzger; P M Schneider; J Park; D Salonga; A H Hölscher; P V Danenberg
Journal:  Clin Cancer Res       Date:  2001-07       Impact factor: 12.531

2.  Increased expression of ornithine decarboxylase messenger RNA in human esophageal carcinoma.

Authors:  K Mafune; Y Tanaka; K Mimori; M Mori; K Takubo; M Makuuchi
Journal:  Clin Cancer Res       Date:  1999-12       Impact factor: 12.531

Review 3.  The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis.

Authors:  A P Meert; B Martin; P Delmotte; T Berghmans; J J Lafitte; C Mascaux; M Paesmans; E Steels; J M Verdebout; J P Sculier
Journal:  Eur Respir J       Date:  2002-10       Impact factor: 16.671

Review 4.  The new World Health Organization classification of lung tumours.

Authors:  E Brambilla; W D Travis; T V Colby; B Corrin; Y Shimosato
Journal:  Eur Respir J       Date:  2001-12       Impact factor: 16.671

5.  Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

Authors:  F V Fossella; R DeVore; R N Kerr; J Crawford; R R Natale; F Dunphy; L Kalman; V Miller; J S Lee; M Moore; D Gandara; D Karp; E Vokes; M Kris; Y Kim; F Gamza; L Hammershaimb
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

6.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

7.  Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

Authors:  Vincent A Miller; Mark G Kris; Neelam Shah; Jyoti Patel; Christopher Azzoli; Jorge Gomez; Lee M Krug; William Pao; Naiyer Rizvi; Barbara Pizzo; Leslie Tyson; Ennapadam Venkatraman; Leah Ben-Porat; Natalie Memoli; Maureen Zakowski; Valerie Rusch; Robert T Heelan
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

Review 8.  The biology of epidermal growth factor receptor in lung cancer.

Authors:  Giorgio V Scagliotti; Giovanni Selvaggi; Silvia Novello; Fred R Hirsch
Journal:  Clin Cancer Res       Date:  2004-06-15       Impact factor: 12.531

9.  Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

Authors:  Fred R Hirsch; Marileila Varella-Garcia; Paul A Bunn; Michael V Di Maria; Robert Veve; Roy M Bremmes; Anna E Barón; Chan Zeng; Wilbur A Franklin
Journal:  J Clin Oncol       Date:  2003-09-02       Impact factor: 44.544

10.  Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer.

Authors:  H S Parra; R Cavina; F Latteri; P A Zucali; E Campagnoli; E Morenghi; G C Grimaldi; M Roncalli; A Santoro
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

View more
  2 in total

1.  Comparative study of imaging and pathological evaluation of pneumonic mucinous adenocarcinoma.

Authors:  Jun Han; Chongchong Wu; Yuxin Wu; Hui Deng; Jie Gao; Hua Han; Xinying Xue
Journal:  Oncol Lett       Date:  2020-12-17       Impact factor: 2.967

Review 2.  Cell Behavior of Non-Small Cell Lung Cancer Is at EGFR and MicroRNAs Hands.

Authors:  Sarah Sayed Hassanein; Sherif Abdelaziz Ibrahim; Ahmed Lotfy Abdel-Mawgood
Journal:  Int J Mol Sci       Date:  2021-11-19       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.